The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Anlotinib: First Global Approval
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sun, Y., Niu, W., Du, F., Du, C., Li, S., Wang, J., Li, L., Wang, F., Hao, Y., Li, C., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0332-8 · Cited by 431
Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1
Lin, B., Song, X., Yang, D., Bai, D., Yao, Y., & Lu, N. (2018) · Gene · doi:10.1016/j.gene.2018.02.026 · Cited by 384
Targeting RTK Signaling Pathways in Cancer
Regad, T. (2015) · Cancers · doi:10.3390/cancers7030860 · Cited by 380
Xie, C., Wan, X., Quan, H., Zheng, M., Fu, L., Li, Y., & Lou, L. (2018) · Cancer Science · doi:10.1111/cas.13536 · Cited by 348
Han, B., Li, K., Zhao, Y., Li, B., Cheng, Y., Zhou, J., Lu, Y., Shi, Y., Wang, Z., Jiang, L., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.478 · Cited by 258
The need for third-line treatment in non-small cell lung cancer: an overview of new options.
Syrigos, K., Saif, M. W., Karapanagiotou, E. M., Oikonomopoulos, G., & de Marinis, F. (2011) · PubMed · Cited by 28
Kalderon, D. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-470-4_8 · Cited by 16
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Qin, S., Li, A., Yi, M., Yu, S., Zhang, M., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0718-5 · Cited by 324
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1796002 · Cited by 108
Metadata
- Authors
- Syed, Y. Y.
- Venue
- Drugs
- Published
- 2018-06-26
- Volume
- 78
- Issue
- 10
- Pages
- 1057-1062
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2810290331
- Cited by
- 268
- References
- 7
- FWCI
- 11.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anlotinib: First Global Approval. https://app.cochat.ai/papers/10.1007/s40265-018-0939-x
- The paper
- Syed, Y. Y. (2018). Anlotinib: First Global Approval. Drugs. https://doi.org/10.1007/s40265-018-0939-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.